Animal models of cardiorenal syndrome: A review

Heart Failure Reviews

Volumn 17, Issue 3, 2012, Pages 411-420

  Szymanski, Mariusz K ^a   De Boer, Rudolf A ^a   Navis, Gerjan J ^a   Van Gilst, Wiek H ^a   Hillege, Hans L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Animal models; Cardiorenal syndrome; Heart kidney interaction

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN ANTAGONIST; ANTIOXIDANT; CREATININE; ERYTHROPOIETIN; LISINOPRIL; NEUROHORMONE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; RENIN INHIBITOR;

ADRENERGIC SYSTEM; ANEMIA; CARDIORENAL SYNDROME; CENTRAL VENOUS PRESSURE; DISEASE ASSOCIATION; DISEASE MODEL; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; INFLAMMATION; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; CARDIO-RENAL SYNDROME; HEART; HEMODYNAMICS; KIDNEY; MODELS, ANIMAL;

EID: 84862522335     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-011-9279-6     Document Type: Review

References (91)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108:2154-2169
3. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134:629-636
4. Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, de Zeeuw D (2003) Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 24:412-420
5. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351:1285-1295
6. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW (2000) The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35:681-689
7. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113:671-678
8. Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD (2006) Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 17:2886-2891
9. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B (2005) The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 26:11-17
10. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52:1527-1539
11. Leithe ME, Margorien RD, Hermiller JB, Unverferth DV, Leier CV (1984) Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation 69:57-64
12. Bock JS, Gottlieb SS (2010) Cardiorenal syndrome: new perspectives. Circulation 121:2592-2600
13. Guyton AC (1990) The surprising kidney-fluid mechanism for pressure control-its infinite gain!. Hypertension 16:725-730
14. Smilde TD, Damman K, van der Harst P, Navis G, Westenbrink BD, Voors AA, Boomsma F, van Veldhuisen DJ, Hillege HL (2009) Differential associations between renal function and ''modifiable'' risk factors in patients with chronic heart failure. Clin Res Cardiol 98:121-129
15. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA (2008) Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 51:1268-1274
16. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL (2009) Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 53:582-588
17. Schrier RW (2006) Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 47:1-8
18. Hirsch AT, Pinto YM, Schunkert H, Dzau VJ (1990) Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 66:22D-30D
19. Weber KT (2001) Aldosterone in congestive heart failure. N Engl J Med 345:1689-1697
20. Ljungman S, Laragh JH, Cody RJ (1990) Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 39 (Suppl 4):10-21
21. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-ofprinciple cohort study. Lancet 373:1275-1281
22. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ (2003) Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 14:425-430
23. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA (1999) Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340:1321-1328
24. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM (2003) Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41:2164-2171
25. Kielstein JT, Bode-Boger SM, Klein G, Graf S, Haller H, Fliser D (2003) Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest 33:370-375
26. Zebrack JS, Anderson JL, Beddhu S, Horne BD, Bair TL, Cheung A, Muhlestein JB (2003) Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J Am Coll Cardiol 42:57-63
27. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103:2055-2059
28. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk HD, Coats AJ, Anker SD (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102:3060-3067
29. Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236-241
30. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL (1996) Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27:1201-1206
31. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, Tatge H, Drexler H (2001) Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 103:799-805
32. Mezzano SA, Ruiz-Ortega M, Egido J (2001) Angiotensin II and renal fibrosis. Hypertension 38:635-638
33. Silverberg DS, Wexler D, Iaina A (2002) The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 4:681-686
34. Lindenfeld J (2005) Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 149:391-401
35. Anand IS (2005) Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med 6 (Suppl 3):S13-S21
36. Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH, van Veldhuisen DJ (2007) Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 28:166-171
37. Al Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ (2001) Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38:955-962
38. de Silva R, Rigby AS, Witte KK, Nikitin NP, Tin L, Goode K, Bhandari S, Clark AL, Cleland JG (2006) Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 98:391-398
39. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M (2000) Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35:250-256
40. Pappas KD, Gouva CD, Katopodis KP, Nikolopoulos PM, Korantzopoulos PG, Michalis LK, Goudevenos JA, Siamopoulos KC (2008) Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovasc Drugs Ther 22:37-44
41. Silverberg DS, Wexler D, Blum M, Iaina A (2003) The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol 60 (Suppl 1):S93-102
42. Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabro A, Campagna SM, Nuti R (2006) Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152:1096.e9-15
43. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777-1782
44. Farbom P, Wahlstrand B, Almgren P, Skrtic S, Lanke J, Weiss L, Kjeldsen S, Hedner T, Melander O (2008) Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: the Nordic diltiazem study. Hypertension 52:115-122
45. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL (2008) Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 10:997-1000
46. Damman K, van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, Bonventre JV, Voors AA, Hillege HL (2010) Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 96:1297-1302
47. Ceiler DL, Schiffers PM, Nelissen-Vrancken HJ, Smits JF (1998) Time-related adaptations in plasma neurohormone levels and hemodynamics after myocardial infarction in the rat. J Card Fail 4:131-138
48. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E (1979) Myocardial infarct size and ventricular function in rats. Circ Res 44:503-512
49. Francis J, Weiss RM, Wei SG, Johnson AK, Felder RB (2001) Progression of heart failure after myocardial infarction in the rat. Am J Physiol Regul Integr Comp Physiol 281:R1734-R1745
50. Feng Q, Lu X, Fortin AJ, Pettersson A, Hedner T, Kline RL, Arnold JM (1998) Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res 37:667-675
51. Hostetter TH, Pfeffer JM, Pfeffer MA, Dworkin LD, Braunwald E, Brenner BM (1983) Cardiorenal hemodynamics and sodium excretion in rats with myocardial infarction. Am J Physiol 245:H98-103
52. Drexler H, Toggart EJ, Glick MR, Heald J, Flaim SF, Zelis R (1986) Regional vascular adjustments during recovery from myocardial infarction in rats. J Am Coll Cardiol 8:134-142
53. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P (1985) Survival after an experimental myocardial infarction: beneficial effects of longterm therapy with captopril. Circulation 72:406-412
54. Smits JF, van Krimpen C, Schoemaker RG, Cleutjens JP, Daemen MJ (1992) Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol 20:772-778
55. van Dokkum RP, Eijkelkamp WB, Kluppel AC, Henning RH, van Goor H, Citgez M, Windt WA, van Veldhuisen DJ, de Graeff PA, de Zeeuw D (2004) Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol 15:3103-3110
56. Dikow R, Schmidt U, Kihm LP, Schaier M, Schwenger V, Gross ML, Katus HA, Zeier M, Hardt SE (2010) Uremia aggravates left ventricular remodeling after myocardial infarction. Am J Nephrol 32:13-22
57. Windt WA, Henning RH, Kluppel AC, Xu Y, de Zeeuw D, van Dokkum RP (2008) Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats. Nephrol Dial Transplant 23:3103-3110
58. Amann K, Tyralla K, Gross ML, Schwarz U, Tornig J, Haas CS, Ritz E, Mall G (2003) Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int 63:1708-1713
59. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G (1992) Reduced capillary density in the myocardium of uremic rats-a stereological study. Kidney Int 42:1079-1085
60. Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E (1988) Myocardial interstitial fibrosis in experimental uremia-implications for cardiac compliance. Kidney Int 33:804-811
61. Mulder P, Richard V, Bouchart F, Derumeaux G, Munter K, Thuillez C (1998) Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Cardiovasc Res 39:600-608
62. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, Tiefenbacher C, Ritz E (2004) Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 15:1530-1536
63. Jie KE, Verhaar MC, Cramer MJ, van der Putten K, Gaillard CA, Doevendans PA, Koomans HA, Joles JA, Braam B (2006) Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 291:F932-F944
64. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2005) Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46:125-133
65. Garcia DL, Anderson S, Rennke HG, Brenner BM (1988) Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 85:6142-6146
66. Bongartz LG, Braam B, Verhaar MC, Cramer MJ, Goldschmeding R, Gaillard CA, Doevendans PA, Joles JA (2010) Transient nitric oxide reduction induces permanent cardiac systolic dysfunction and worsens kidney damage in rats with chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 298:R815-R823
67. Baylis C, Mitruka B, Deng A (1992) Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90:278-281
68. Gardiner SM, Compton AM, Kemp PA, Bennett T (1990) Regional and cardiac haemodynamic effects of NG-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br J Pharmacol 101:625-631
69. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, Utsumi H, Takeshita A (2000) Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 87:392-398
70. Noiri E, Nagano N, Negishi K, Doi K, Miyata S, Abe M, Tanaka T, Okamoto K, Hanafusa N, Kondo Y, Ishizaka N, Fujita; T (2006) Efficacy of darbepoetin in doxorubicin-induced cardiorenal injury in rats. Nephron Exp Nephrol 104:e6-e14
71. Mihailovic-Stanojevic N, Jovovic D, Miloradovic Z, Grujic- Milanovic J, Jerkic M, Markovic-Lipkovski J (2009) Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan. Nephrol Dial Transplant 24: 1142-1150
72. Taniyama Y, Walsh K (2002) Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. J Mol Cell Cardiol 34:1241-1247
73. Ulu N, Buikema H, van Gilst WH, Navis G (2008) Vascular dysfunction in adriamycin nephrosis: different effects of adriamycin exposure and nephrosis. Nephrol Dial Transplant 23:1854-1860
74. Patten RD, Hall-Porter MR (2009) Small animal models of heart failure: development of novel therapies, past and present. Circ Heart Fail 2:138-144
75. Balakumar P, Singh AP, Singh M (2007) Rodent models of heart failure. J Pharmacol Toxicol Methods 56:1-10
76. Yang HC, Zuo Y, Fogo AB (2010) Models of chronic kidney disease. Drug Discov Today Dis Models 7:13-19
77. Liao Y, Ishikura F, Beppu S, Asakura M, Takashima S, Asanuma H, Sanada S, Kim J, Ogita H, Kuzuya T, Node K, Kitakaze M, Hori M (2002) Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation. Am J Physiol Heart Circ Physiol 282:H1703-H1708
78. Bayat H, Swaney JS, Ander AN, Dalton N, Kennedy BP, Hammond HK, Roth DM (2002) Progressive heart failure after myocardial infarction in mice. Basic Res Cardiol 97:206-213
79. Wu JC, Nasseri BA, Bloch KD, Picard MH, Scherrer-Crosbie M (2003) Influence of sex on ventricular remodeling after myocardial infarction in mice. J Am Soc Echocardiogr 16:1158-1162
80. Liu YH, Yang XP, Nass O, Sabbah HN, Peterson E, Carretero OA (1997) Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol 272:H722-H727
81. Ma LJ, Fogo AB (2003) Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int 64:350-355
82. Bing OH, Brooks WW, Robinson KG, Slawsky MT, Hayes JA, Litwin SE, Sen S, Conrad CH (1995) The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol 27:383-396
83. Inoko M, Kihara Y, Morii I, Fujiwara H, Sasayama S (1994) Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. Am J Physiol 267:H2471-H2482
84. Remuzzi G, Perico N, Macia M, Ruggenenti P (2005) The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int 99 (Suppl):S57-65
85. Remuzzi A, Puntorieri S, Mazzoleni A, Remuzzi G (1988) Sex related differences in glomerular ultrafiltration and proteinuria in Munich-Wistar rats. Kidney Int 34:481-486
86. Tachibana H, Naga Prasad SV, Lefkowitz RJ, Koch WJ, Rockman HA (2005) Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation 111:591-597
87. de Boer RA, Pokharel S, Flesch M, van Kampen DA, Suurmeijer AJ, Boomsma F, van Gilst WH, van Veldhuisen DJ, Pinto YM (2004) Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR (mRen2)27. J Mol Med 82:678-687
88. Ross J Jr (2002) Dilated cardiomyopathy: concepts derived from gene deficient and transgenic animal models. Circ J 66:219-224
89. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM (1997) Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81:627-635
90. Smith JD, Breslow JL (1997) The emergence of mouse models of atherosclerosis and their relevance to clinical research. J Intern Med 242:99-109
91. Huang WY, Aramburu J, Douglas PS, Izumo S (2000) Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy. Nat Med 6:482-483